JC06 Rec'd PCT/PTO 07 APR 2005

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Date: April 7, 2005 Page 1 of 1

Attorney Docket No.	Client Ref. 10/530567
056291-5203	
Applicant: Alan BARGE	#2
Appln. No.: Unassigned	
Filing Date: April 7, 2005	
Examiner: Unassigned	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR						
	BR						
	CR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	DR	~~04/32654~~	~~05/2001~~	~~WO~~	~~Hennequin et al.~~				
	ER								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	FR	~~Giordiello et al., Antitumor Effects of ZD6474, A Small Molecule VEGF Receptor Tyrosine Kinase Inhibitor That Is Also Active Against EGF Receptor Tyrosine Kinase, Proceedings of the American Association for Cancer Research Annual Vol. 43, March 2002, pp. 1080-1081~~
	GR	~~Drevs et al., Effect of ZD6474, A VEGF Receptor Tyrosine Kinase Inhibitor, on Primary Tumor Growth, Metastasis, Vessel Density and Microvascular Architecture in Murine Renal Cell Carcinoma, Proceedings of the American Association for Cancer Research Annual, Vol. 43, March 2002, pp. 1082~~
	HR	~~Wedge et al., Combination of the VEGF Receptor Tyrosine Kinase Inhibitor ZD6474 and Vascular Targeting Agent ZD6126 Produced an Enhanced Antitumor Response, Proceedings of the American Association for Cancer Research Annual, Vol. 43, March 2002, pp. 1081~~
	IR	~~Holden et al., Effects of ZD6474, An Orally Active Inhibitor of VEGF Receptor Tyrosine Kinase, In Patients With Solid Tumors: Results From A Phase I Study, European Journal of Cancer, Pergamon Press, Vol. 37, No. Supplement 6, October 2001, pp. S73~~
	JR	~~Hennequin et al., Novel 4-Anilinoquinazolines With C-7 Basic Side Chains: Design and Structure Activity Relationship Of A Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors, Journal Of Medicinal Chemistry, American Chemical Society, Vol. 45, No. 6, March 14, 2002, pp. 1300-1312~~
	KR	~~Gianccone et al., ZD1839 ('Iressa'), An Orally Active, Selective, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (egfr-tki), Is Well Tolerated In Combination With Gemcitabine And Cisplatin, In Patients With Advanced Solid Tumours: Preliminary Tolerability, Efficacy And Pharmacokinetic Results, European Journal of Cancer, Vol 37, No. Supplement 6, October 2001, pp. S30, S34~~
	LR	

Examiner	/Meghan Finn/	Date Considered:	11/18/2007

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.